Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 16Myelodysplastic Syndromes 9Leukemia, Myelomonocytic, Chronic 4Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Multiple Myeloma 2Lymphoma, Large B-Cell, Diffuse 2Leukemia 2Advanced Solid Neoplasm 2Thrombocytosis 1Thrombocythemia, Essential 1Solid Tumors 1Renal Insufficiency 1Primary Myelofibrosis 1Polycythemia Vera 1Neoplasm, Residual 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Mesothelioma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Liver Diseases 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Neutrophilic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1

Interventions

pembrolizumab 300Nivolumab 273Ipilimumab 250aldesleukin 137Cyclophosphamide 136Interleukin-2 105trametinib 82dabrafenib 76Temozolomide 75Dacarbazine 74Vemurafenib 71fludarabine 68fludarabine phosphate 62Biopsy 49binimetinib 47sargramostim 44Radiosurgery 44Bevacizumab 43Paclitaxel 42encorafenib 40incomplete Freund's adjuvant 39atezolizumab 38Radiotherapy 37Cisplatin 36CTLA-4 Antigen 36Specimen Handling 35Magnetic Resonance Spectroscopy 35Carboplatin 35cobimetinib 34Introns 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × pevonedistat × Clear all
NCT01011530 2013-07-16

Dose Escalation Study of MLN4924 in Adults With Melanoma

Millennium Pharmaceuticals, Inc.

Phase 1 Completed
37 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡